Wanda L DeKrey

Publications (2)16.65 Total impact

• Article: Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3.

  Debra L Barton, Donald B Wender, Jeff A Sloan, Robert J Dalton, Ernie P Balcueva, Pamela J Atherton, Albert M Bernath, Wanda L DeKrey, Tim Larson, James D Bearden, Paul C Carpenter, Charles L Loprinzi
  [show abstract] [hide abstract]
  ABSTRACT: Decreased libido is one of several changes in sexual function that are often experienced by female cancer patients. Transdermal testosterone therapy has been associated with increased libido among estrogen-replete women who report low libido. In a phase III randomized, placebo-controlled crossover clinical trial, we evaluated whether transdermal testosterone would increase sexual desire in female cancer survivors. Postmenopausal women with a history of cancer and no current evidence of disease were eligible if they reported a decrease in sexual desire and had a sexual partner. Eligible women were randomly assigned to receive 2% testosterone in Vanicream for a testosterone dose of 10 mg daily or placebo Vanicream for 4 weeks and were then crossed over to the opposite treatment for an additional 4 weeks. The primary endpoint was sexual desire or libido, as measured using the desire subscales of the Changes in Sexual Functioning Questionnaire, as assessed at baseline and at the end of 4 and 8 weeks of treatment. Serum levels of bioavailable testosterone were measured at the same times. All statistical tests were two-sided. We enrolled 150 women. Women who were on active testosterone cream had higher serum levels of bioavailable testosterone than women on placebo (mean change from baseline, testosterone versus placebo, week 4, 11.57% versus 0%, difference = 11.57%, 95% confidence interval [CI] = 8.49% to 14.65%; week 8, 10.21% versus 0.28%, difference = 9.92%, 95% CI = 5.42% to 14.42%; P<.001 for all). However, the average intrapatient libido change from baseline to weeks 4 and 8 was similar on both arms. Increased testosterone level did not translate into improved libido, possibly because women on this study were estrogen depleted.
  CancerSpectrum Knowledge Environment 06/2007; 99(9):672-9. · 14.07 Impact Factor
• Source

  Available from: mayo.edu

  Article: Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting.

  Gary A Croghan, Jeff A Sloan, Ivana T Croghan, Paul Novotny, Richard D Hurt, Wanda L DeKrey, James A Mailliard, Larry P Ebbert, Debra K Swan, Daniel J Walsh, Martin Wiesenfeld, Ralph Levitt, Philip Stella, Patricia A Johnson, Loren K Tschetter, Charles Loprinzi
  [show abstract] [hide abstract]
  ABSTRACT: This multicenter, randomized, open-label clinical trial was conducted to determine whether the combined use of nicotine patch therapy and a nicotine nasal spray would improve smoking abstinence rates compared to either treatment alone, without behavioral counseling. Data were collected at 15 regional cancer control oncology centers within the North Central Cancer Treatment Group. Of the 1384 smokers randomized to the study, 20% were abstinent from smoking at 6 weeks and 8% were abstinent at 6 months. At 6 weeks, the 7-day point prevalence smoking abstinence rate for the patch alone (21.1%) was superior to the spray (13.6%) but was significantly lower than the rate for combination therapy (27.1%). At 6 months, the 7-day point prevalence abstinence rates were not significantly different among the three groups. Combination nicotine nasal spray and nicotine patches were delivered safely in a nonspecialized outpatient clinical setting and enhanced short-term smoking abstinence rates, but these rates were not sustained at 6 months.
  Nicotine & Tobacco Research 05/2003; 5(2):181-7. · 2.58 Impact Factor